(Q37532912)

English

Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC.

scientific article published on 12 February 2009

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. (English)

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

zoledronic acid

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

5

object named as

Edith A Perez

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

author name string

Stephanie L Hines

1

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Betty Mincey

2

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Todor Dentchev

3

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Jeff A Sloan

4

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

David B Johnson

6

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Paul L Schaefer

7

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Steve Alberts

8

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Heshan Liu

9

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Stephen Kahanic

10

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Miroslaw A Mazurczak

11

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Daniel A Nikcevich

12

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Charles L Loprinzi

13

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

language of work or name

0 references

publication date

12 February 2009

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

117

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

3

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

603-609

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3907065

23 August 2017

Aromatase inhibitors and bone loss

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3907065

23 August 2017

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3907065

23 August 2017

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3907065

23 August 2017

Intravenous zoledronic acid in postmenopausal women with low bone mineral density

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3907065

23 August 2017

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3907065

23 August 2017

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3907065

1 September 2018

Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3907065

1 September 2018

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety upda

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3907065

1 September 2018

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3907065

1 September 2018

Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3907065

1 September 2018

Predictive Value of BMD for Hip and Other Fractures

1 reference

https://pubmed.ncbi.nlm.nih.gov/19214743

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17

1 reference

https://pubmed.ncbi.nlm.nih.gov/19214743

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

1 reference

https://pubmed.ncbi.nlm.nih.gov/19214743

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19214743

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230)

1 reference

https://pubmed.ncbi.nlm.nih.gov/19214743

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10549-009-0332-2

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37532912&oldid=2200506897"